The current risk assessment score of Cybin Inc is 3.80, ranking 129 out of 403 in the Biotechnology & Medical Research industry. The company's beta value is 0.13. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.